KUALA LUMPUR, Malaysia, Jan. 26 /PRNewswire/ -- PhenoMed Sdn Bhd, a development-stage disease management and medical-pharmaceutical therapeutic company, announces the initiation of its clinical trials program for infectious diseases.
"PhenoMed is announcing that it will begin collecting information from government agencies, physicians and individual patients interested in participating in the company's clinical trials program. We are working closely with our US partner, GenoMed, Inc., and that company's CEO and Chief Medical Officer, Dr. David Moskowitz, in helping to sign up interested parties," said Ezehan Reza Kamaluddin, PhenoMed's interim Chief Operating Officer. "There is a worldwide need for disease management and targeted pharmaceutical therapeutics directed at infectious disease. Malaysia's disease management needs are ever-present and PhenoMed wants to do all it can to help in meeting the country's healthcare needs. The immediate concerns over avian flu in the region highlights this need."
PhenoMed's US partner, GenoMed, believes it has discovered a way to accomplish the equivalent of vaccination against all viruses, a kind of "universal vaccine" against most viral diseases. The method involves blocking angiotensin II, an approach already known to be extremely safe from its use, for other purposes, in hundreds of millions of patients since 1978. This patent-pending method is presently under study by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, to test the Company's compounds in tissue culture assays to evaluate potential activity against influenza (the flu) and SARS.
About PhenoMed, Sdn Bhd
PhenoMed is a development-stage disease management and medical- pharmaceutical therapeutic company, with its primary goal being the improvement of patient outcomes through the discovery and application of "genome-aware therapeutics(TM)". PhenoMed is building a network of physician and health services organizations to quickly expand its medical and therapeutic service offerings throughout the Asia-Pacific region. Founded in 2003, PhenoMed is a privately held company located in Kuala Lumpur, Malaysia. For more information about the company, please visit http://www.phenomed.net/.
Ezehan Reza Kamaluddin
Chief Operating Officer (Interim)
28-1, Level 1, Jalan 28/70A
Desa Sri Hartamas
50480 Kuala Lumpur, Malaysia
About GenoMed, Inc.
GenoMed, Inc. is a next generation disease management company whose mission is the improvement of patient outcomes through the identification of molecular pathways that cause disease. As first reported in a St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html), the company has applied for patents based on its finding that the ACE gene is associated with a large number of common diseases including virtually all autoimmune diseases. GenoMed is currently conducting worldwide clinical trials for SARS and influenza A (the flu). In September of 2003, GenoMed obtained an 88% cure rate for this treatment approach against another lethal viral disease, West Nile virus encephalitis. These results will be published soon.
David W. Moskowitz MD, MA (Oxon.), FACP
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com/.
PhenoMed Sdn Bhd
CONTACT: Ezehan Reza Kamaluddin, Chief Operating Officer (Interim),PhenoMed, email@example.com; or David W. Moskowitz MD, MA (Oxon.), FACP,GenoMed, +1-314-977-0110, fax: +1-314-977-0042, firstname.lastname@example.org